Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Abbott presented Beta-CORRECT data at ESMO 2026 showing its whole-genome sequencing Oncodetect MRD test achieved 72.2% sensitivity for colorectal cancer recurrence detection, a 30-percentage-point absolute improvement over the WES version at 42.2%. In the 279-patient study, patients with detectable post-surgical ctDNA had a 10.6-fold higher recurrence risk, with two-year disease-free survival of 36.2% versus 92.3% for ctDNA-negative patients.
Key figures
- Drug Name
- Oncodetect (WGS-based MRD test)
- Phase Of Trial
- Beta-CORRECT clinical validation study (stage II, III, resectable stage IV colorectal cancer)
- Patients analyzed
- 279
- Sensitivity wes pct
- 42.2
- Sensitivity wgs pct
- 72.2
- Dna variants tracked
- up to 5,000
- Recurrence risk ratio
- 10.6-fold higher with detectable ctDNA
- Two year dfs ctdna negative pct
- 92.3
- Two year dfs ctdna positive pct
- 36.2
- Absolute sensitivity improvement pct
- 30
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.